309 related articles for article (PubMed ID: 26035702)
1. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
[TBL] [Abstract][Full Text] [Related]
2. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
Socinski MA; Langer CJ; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Zhang H; Renschler MF
Ann Oncol; 2013 Feb; 24(2):314-321. PubMed ID: 23123509
[TBL] [Abstract][Full Text] [Related]
5. Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Cortes J; Pérez-García J; Whiting S; Wan Y; Solem C; Tai MH; Margunato-Debay S; Ko A; Fandi A; Botteman M
Clin Breast Cancer; 2018 Oct; 18(5):e919-e926. PubMed ID: 29703690
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
[TBL] [Abstract][Full Text] [Related]
10. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.
Hirsh V; Wan Y; Lin FJ; Margunato-Debay S; Ong TJ; Botteman M; Langer C
Clin Lung Cancer; 2018 Sep; 19(5):401-409.e4. PubMed ID: 29903552
[TBL] [Abstract][Full Text] [Related]
11. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
12. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
[TBL] [Abstract][Full Text] [Related]
13. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
15. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA
Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Wang Z; Huang C; Yang JJ; Song Y; Cheng Y; Chen GY; Yan HH; Ben XS; Wang BC; Xu CR; Jiang BY; Zhou Q; Chen HJ; Wu YL
Eur J Cancer; 2019 Mar; 109():183-191. PubMed ID: 30739019
[TBL] [Abstract][Full Text] [Related]
17. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Jin F; Zhu H; Shi F; Kong L; Yu J
Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
